CSG's Ammunition Pipeline Keeps Flowing as the Order Book Tops €17 Billion

CSG secures €100M Dezamet ammo deal, H1 revenue up 17.2% to €3.3B, NATO share rises as Ukraine share falls.

The Czech defence conglomerate CSG has spent the past month quietly stacking up ammunition contracts that, taken together, tell a clearer story than any single headline-grabbing vehicle deal. The latest addition: a supply agreement signed on 24 July and disclosed last Tuesday under which Polish subsidiary CSG Polska will deliver pyrotechnic components and fuse assemblies for 155-mm artillery rounds to Dezamet S.A. The pact, valued at more than €100 million, is described by both parties as the fruit of a long-running collaboration in munitions manufacturing.

That award follows hard on the heels of a separate framework agreement between CSG's Federal Ammunition arm and the Nordic Police, covering up to 35 million rounds of service and training ammunition over an extended delivery period. Together, the two contracts underscore a deliberate strategy: while bridge-layer vehicles and armoured platforms generate the headlines, the munitions business is engineered to deliver the kind of recurring, capacity-filling revenue that project-based work cannot match.

A Half-Year Scorecard That Backs the Optimism

The contract flow arrived alongside a set of interim results that gave investors plenty to digest. On 7 August, CSG reported first-half revenue of €3.3 billion, up 17.2 percent year on year, with operating EBIT climbing 13 percent to €784 million. The EBIT margin held steady at 24.1 percent, sitting comfortably inside the company's guided range. Net profit for the second quarter alone jumped 261 percent to €272.0 million on revenue of €1.71 billion, an 18 percent increase.

The Land Systems division deserves particular attention: its revenue doubled year on year to €445 million, and it now accounts for 46 percent of the group's order backlog, which has swelled to €17 billion. Perhaps more telling for the long-term investment case, the share of revenue derived from Ukraine has fallen from 27 percent to 17 percent, while NATO markets have gained ground — evidence that CSG is increasingly anchoring its growth to Western defence budgets rather than a single conflict zone.

Management used the results to reaffirm its full-year guidance of €7.4 billion to €7.6 billion in revenue at an EBIT margin between 24 and 25 percent. The company also flagged an expected release of €1.5 billion in working capital during the second half, which should provide additional balance-sheet relief.

Regulatory Approvals and a Wider Industrial Footprint

Beyond the contract wins, CSG has been quietly expanding its corporate structure. Germany's Federal Cartel Office has cleared the acquisition of minority stakes in two Hungarian companies — an indirect 36.75 percent interest in RÁBA Nyrt and a direct 49 percent holding in Hirtenberger Defence Systems Kft, both purchased from 4iG Space and Defence Plc. The green light gives CSG a broader industrial base in Central Europe and complements the minority position it took in North Vector Dynamics Inc. earlier this month, the value of which was not disclosed.

The Share Price Tells a Two-Tempo Story

For all the operational momentum, the equity has been anything but calm. On Friday, the stock fell 2.3 percent to close at €18.68, caught in a broader sell-off of European technology and industrial names as traders braced for fresh US sanctions on Iran and awaited Federal Reserve commentary on monetary policy. The drop, however, looks more macro-driven than company-specific — over the past 30 days the shares have still managed a 12 percent gain, and on a weekly basis the stock is up 2.2 percent.

The technical picture reinforces that resilience. The shares trade roughly 15 percent above their 50-day moving average of €16.18, suggesting the recovery from the summer lows remains intact despite Friday's wobble. The market capitalisation stands at just under €19 billion, with annualised volatility of 59 percent serving as a reminder that this remains a stock for the stout-hearted.

The Dezamet contract, modest as it is relative to the €17 billion backlog, does little to alter that fundamental equation. What it does do is strengthen the thesis that CSG is methodically cementing its position as a European ammunition supplier of scale — a factor that, alongside the confirmed guidance and the growing NATO revenue mix, is likely to matter more to the share price over time than any single day's trading noise.